Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants

Jules Lin, Lin Lin, Dafydd G. Thomas, Joel K. Greenson, Thomas J. Giordano, Gregory S. Robinson, Ruteja A. Barve, Frank A. Weishaar, Jeremy M.G. Taylor, Mark B. Orringer, David G. Beer

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Purpose: The melanoma-associated antigens (MAGEs) are tumor-specific antigens recognized by cytotoxic T lymphocytes. In this study, expression of MAGE family A members was evaluated during the development of esophageal adenocarcinoma (EA) as potential targets for immunotherapy. Experimental Design: MAGE-A mRNA expression was evaluated in 46 samples including Barrett's metaplasia (BM), dysplasia, and EA using oligonucleotide microarrays. Expression of MAGE-A proteins was confirmed by immunohistochemistry on tissue microarrays containing 59 EA, 11 dysplasia, and 9 BM samples and by Western blot. To further evaluate MAGE-A10 expression, reverse transcription-polymerase chain reaction (RT-PCR) products were sequenced, and protein expression was determined using a specific antibody. Results: Overexpression of MAGE-A1, MAGE-A2b, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, and MAGE-A12 was found in EAs relative to BM on oligonucleotide microarrays. MAGE-A3 overexpression was confirmed by real-time RT-PCR in 21.4% (6 of 28) of esophageal tumors. Immunohistochemistry on tissue microarray revealed MAGE-A proteins in 20.3% (12 of 59) of EAs and MAGE-A10 staining in 16.9% (10 of 59) of EAs. MAGE-A expression was confirmed by Western blot in several esophageal tumors and in two EA cell lines, Flo-1 and Seg-1, whereas Flo-1 also expressed MAGE-A10. Tumors produced from these cell lines in nude mice retained MAGE-A expression. Interestingly, RT-PCR in primary tumors expressing MAGE-A10 protein revealed additional PCR products that were identified as novel MAGE-A10 alternative splice variants using DNA sequencing. Conclusions: This is the first report of these MAGE-A10 alternative splice sequences, and characterization of MAGE-A expression may provide potential targets for immunotherapy in patients with EA.

Original languageEnglish
Pages (from-to)5708-5716
Number of pages9
JournalClinical Cancer Research
Volume10
Issue number17
DOIs
StatePublished - Sep 1 2004

Fingerprint Dive into the research topics of 'Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants'. Together they form a unique fingerprint.

  • Cite this

    Lin, J., Lin, L., Thomas, D. G., Greenson, J. K., Giordano, T. J., Robinson, G. S., Barve, R. A., Weishaar, F. A., Taylor, J. M. G., Orringer, M. B., & Beer, D. G. (2004). Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants. Clinical Cancer Research, 10(17), 5708-5716. https://doi.org/10.1158/1078-0432.CCR-04-0468